Impax Laboratories Inc (IPXL)

15.75
0.00 (0.00)
NASDAQ : Health Care
Prev Close 15.75
Open 15.70
Day Low/High 15.45 / 16.18
52 Wk Low/High 27.62 / 50.74
Volume 856.42K
Avg Volume 2.49M
Exchange NASDAQ
Shares Outstanding 73.70M
Market Cap 1.16B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

IPXL Crosses Above Average Analyst Target

IPXL Crosses Above Average Analyst Target

In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $12.00, changing hands for $12.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Impax Laboratories Stock Sees Short Interest Drop 32.3%

Impax Laboratories Stock Sees Short Interest Drop 32.3%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,670,394 share decrease in total short interest for Impax Laboratories Inc , to 3,500,878, a decrease of 32.30% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.

Skincare Makers Lead Biotech Movers

Skincare Makers Lead Biotech Movers

Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.

Impax Board Of Directors Appoints Paul M. Bisaro President And CEO

Impax Board Of Directors Appoints Paul M. Bisaro President And CEO

Industry Veteran Brings a Successful Record of Operational Execution, Driving Transformation and Delivering Growth

First Week Of IPXL May 19th Options Trading

First Week Of IPXL May 19th Options Trading

Investors in Impax Laboratories Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IPXL options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Oversold Conditions For Impax Laboratories (IPXL)

Oversold Conditions For Impax Laboratories (IPXL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

First Week of IPXL September 15th Options Trading

First Week of IPXL September 15th Options Trading

Investors in Impax Laboratories Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.